Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Merck boosts infectious disease assets in $3.7bn Idenix purchase

Executive Summary

Beating out other rumored bidders including AbbVie Inc. and Johnson & Johnson, Merck & Co. Inc. paid $24.50 per share (a 264% premium), or $3.7bn total, to buy publicly traded Idenix Pharmaceuticals Inc. (viral diseases). At just over $4bn in sales last year, Merck’s infectious disease portfolio (not including vaccines) made up 11% of the company’s pharma sales. Idenix may improve that number, although the first drug to come out of the acquisition is years away at the least.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash

Related Companies

UsernamePublicRestriction

Register